<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02131194</url>
  </required_header>
  <id_info>
    <org_study_id>1-tunis</org_study_id>
    <nct_id>NCT02131194</nct_id>
  </id_info>
  <brief_title>The Post-Vitrectomy Lenstatin™ Study</brief_title>
  <official_title>The Post-Vitrectomy Lenstatin Study: A Prospective Randomized Double Blind Human Clinical Trial Testing the Efficacy of Lenstatin in Inhibiting Cataract Formation and Progression After Pars Plana Vitrectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lenstatin LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lenstatin LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the efficacy of Lenstatin™, an over-the-counter nutritional supplement, in&#xD;
      inhibiting the progression of nuclear cataract in eyes after pars plana vitrectomy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND AND RATIONALE&#xD;
&#xD;
      There are conflicting reports on the effectiveness of nutritional antioxidants in preventing&#xD;
      or slowing the growth of age related cataracts, despite extensive laboratory evidence&#xD;
      suggesting that oxidative damage to lens epithelial cells is a common underlying etiologic&#xD;
      factor in cataractogenesis. One reported review of nine clinical trials involving over&#xD;
      117,000 patients suggested that beta-carotene, Vitamin E, and Vitamin C had no effect in&#xD;
      preventing or slowing the progression of age-related cataract. Conversely, a randomized trial&#xD;
      of over 14,000 US male physicians indicated that long-term daily multivitamin use modestly&#xD;
      and significantly decreased the risk of cataract.&#xD;
&#xD;
      Cataract formation following pars plana vitrectomy is a well recognized post-operative&#xD;
      complication of the procedure, with the reported incidence of clinically significant cataract&#xD;
      development as high as 80% within 2 years after pars plana vitrectomy.&#xD;
&#xD;
      INVESTIGATIONAL AGENT&#xD;
&#xD;
      Lenstatin™ is a proprietary formulated nutritional supplement containing 11 micronutrients&#xD;
      and anti-oxidants intended to be taken for the nutritional support of the human crystalline&#xD;
      lens.&#xD;
&#xD;
      INTERVENTION&#xD;
&#xD;
      Participants will be randomized to treatment with Lenstatin or Placebo for (6) months&#xD;
      following pars plana vitrectomy.&#xD;
&#xD;
      STUDY METHODS&#xD;
&#xD;
      Participants will have baseline nuclear density (cataract) measurements using the Pentacam&#xD;
      Nucleus Staging (PNS) program. The Pentacam Scheimpflug imaging system is a non-contact and&#xD;
      non-invasive anterior segment imaging device which has been shown to provide an immediate,&#xD;
      quantitative, examiner-independent measurement of lens density which correlates with the LOCS&#xD;
      III cataract grade. Serial Pentacam nuclear density measurements will be taken on each&#xD;
      participant at (1) month intervals for (6) months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pentacam Nuclear Density Measurements</measure>
    <time_frame>(6) months</time_frame>
    <description>The endpoint for determining the efficacy of Lenstatin in inhibiting cataract growth is a 95% confidence level of a statistically significant greater than 5% reduction in the rate of of increase in Pentacam nuclear density measurements in the Lenstatin™ treatment group compared to the placebo treatment group at 6 months postoperative pars plana vitrectomy.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Cataract, Nuclear Progressive</condition>
  <arm_group>
    <arm_group_label>Lenstatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lenstatin (2) capsules orally per day for (6) months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugar Pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo manufactured to mimic Lenstatin (2) capsules orally per day for (6) months</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lenstatin</intervention_name>
    <description>Dietary Supplement Lenstatin</description>
    <arm_group_label>Lenstatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo sugar pill manufactured to mimic Lenstatin</description>
    <arm_group_label>Sugar Pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults over the age of 18&#xD;
&#xD;
          -  Post pars plana vitrectomy surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pediatric patients under the age of 18&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Hypersensitivity to any of the ingredients in Lenstatin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott W Tunis, MD FACS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lenstatin LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Scott W. Tunis MD FACS</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <study_first_submitted>May 2, 2014</study_first_submitted>
  <study_first_submitted_qc>May 5, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2014</study_first_posted>
  <last_update_submitted>December 3, 2015</last_update_submitted>
  <last_update_submitted_qc>December 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cataract</keyword>
  <keyword>Nutritional Supplement</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

